These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2802553)

  • 1. Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.
    Dhillon J; Mitchison DA
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1255-9. PubMed ID: 2802553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.
    Dickinson JM; Aber VR; Mitchison DA
    Am Rev Respir Dis; 1977 Oct; 116(4):627-35. PubMed ID: 411404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
    Burhan E; Ruesen C; Ruslami R; Ginanjar A; Mangunnegoro H; Ascobat P; Donders R; van Crevel R; Aarnoutse R
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3614-9. PubMed ID: 23689725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles.
    Clemens DL; Lee BY; Xue M; Thomas CR; Meng H; Ferris D; Nel AE; Zink JI; Horwitz MA
    Antimicrob Agents Chemother; 2012 May; 56(5):2535-45. PubMed ID: 22354311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Culture and susceptibility testing of mycobacteria with VersaTREK].
    Gravet A; Souillard N; Habermacher J; Moser A; Lohmann C; Schmitt F; Delarbre JM
    Pathol Biol (Paris); 2011 Feb; 59(1):32-8. PubMed ID: 20850229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin.
    Ahn C; Oh KH; Kim K; Lee KY; Lee JG; Oh MD; Kim Y; Han JS; Kim S; Lee JS; Jang IJ; Shin SG
    Perit Dial Int; 2003; 23(4):362-7. PubMed ID: 12968844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases.
    Yamori S; Ichiyama S; Shimokata K; Tsukamura M
    Microbiol Immunol; 1992; 36(4):361-8. PubMed ID: 1406364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro.
    Khor M; Lowrie DB; Mitchison DA
    Br J Exp Pathol; 1986 Oct; 67(5):707-17. PubMed ID: 3098272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages.
    Heifets L; Higgins M; Simon B
    Int J Tuberc Lung Dis; 2000 Jun; 4(6):491-5. PubMed ID: 10864178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis.
    Ge Z; Wang Z; Wei M
    Eur Spine J; 2008 Nov; 17(11):1482-7. PubMed ID: 18795341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India.
    Trivedi SS; Desai SG
    Tubercle; 1988 Mar; 69(1):37-42. PubMed ID: 3140458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
    Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.
    Somoskovi A; Parsons LM; Salfinger M
    Respir Res; 2001; 2(3):164-8. PubMed ID: 11686881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
    Dhillon J; Dickinson JM; Sole K; Mitchison DA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model.
    Sarkar S; Sarkar D
    J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.